Daunomycin
Acute Myelomonocytic Leukemia M4
National Cancer Institute (NCI)Small moleculePhase 3Active
BBB
77/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 68/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Acute Myelomonocytic Leukemia M4 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Stanford University | Phase 3 | BBB |
Cytarabine University of Alberta | Phase 3 | BBB |
Cyclophosphamide ECOG-ACRIN Cancer Research Group | Phase 3 | BBB |
Idarubicin University of Alberta | Phase 3 | BBB |
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Daunomycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →